Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: PR Newswire
NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoringSTAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial – overseeing all coronary plaque and inflammation measurements and monitoring.The REMBRANDT trial, sponsored by NewAmsterdam Pharma (Nasdaq: NAMS), is a placebo-controlled, double-blind, randomized trial designed to assess the efficacy of obicetrapib and ezetimibe fixed dose combination (FDC) on coronary plaque burden. Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that has shown to lower low-density lipoprotein cholesterol (LDL-C) in three Phase 3 clinical trials. Favorable changes in noncalcified coro
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in DecemberGlobeNewswire
- NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]Seeking Alpha
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
NAMS
Sec Filings
- 12/4/25 - Form SCHEDULE
- 12/2/25 - Form 144
- 12/2/25 - Form 144
- NAMS's page on the SEC website